Pfizer revs up to leave GSK in the dust as maternal RSV vax granted FDA breakthrough tagnews2022-03-02T14:15:35+00:00March 2nd, 2022|FierceBiotech|
FDA slaps hold on Finch’s C. diff med to get info on COVID-19 screening for donor-derived therapynews2022-03-02T14:00:33+00:00March 2nd, 2022|FierceBiotech|
Novartis backs Epsilogen’s bid to turn ‘Cinderella antibody’ into new class of cancer drugnews2022-03-02T11:04:25+00:00March 2nd, 2022|FierceBiotech|
Facing omicron ‘curveball,’ Inovio seeks endpoint switch amid fear it will strike out against original goalnews2022-03-02T09:39:46+00:00March 2nd, 2022|FierceBiotech|
Sanofi picks a ‘safe’ bet for Adagene’s antibody tech in $2.5B biobucks tie upnews2022-03-02T01:05:54+00:00March 2nd, 2022|FierceBiotech|
Flagship unveils Vesalius with $75M to bankroll ambitious target of treating 90% of human illnessesnews2022-03-01T19:27:16+00:00March 1st, 2022|FierceBiotech|
Epizyme trims workforce, pipeline for FDA-approved cancer drug Tazverik in cost-saving movenews2022-03-01T18:18:57+00:00March 1st, 2022|FierceBiotech|
RedHill’s second-try COVID pill staves off hospitalization in phase 2news2022-03-01T16:42:45+00:00March 1st, 2022|FierceBiotech|
RedHill’s 2nd try COVID pill staves off hospitalization in phase 2news2022-03-01T16:42:45+00:00March 1st, 2022|FierceBiotech|
AbbVie bets $130M on UCB spinout, bagging early-phase Alzheimer’s and depression prospectnews2022-03-01T13:47:34+00:00March 1st, 2022|FierceBiotech|
